Literature DB >> 23574406

Methamphetamine-induced neurotoxicity disrupts naturally occurring phasic dopamine signaling.

Christopher D Howard1, David P Daberkow, Eric S Ramsson, Kristen A Keefe, Paul A Garris.   

Abstract

Methamphetamine (METH) is a highly addictive drug that is also neurotoxic to central dopamine (DA) systems. Although striatal DA depletions induced by METH are associated with behavioral and cognitive impairments, the link between these phenomena remains poorly understood. Previous work in both METH-pretreated animals and the 6-hydroxydopamine model of Parkinson's disease suggests that a disruption of phasic DA signaling, which is important for learning and goal-directed behavior, may be such a link. However, previous studies used electrical stimulation to elicit phasic-like DA responses and were also performed under anesthesia, which alters DA neuron activity and presynaptic function. Here we investigated the consequences of METH-induced DA terminal loss on both electrically evoked phasic-like DA signals and so-called 'spontaneous' phasic DA transients measured by voltammetry in awake rats. Not ostensibly attributable to discrete stimuli, these subsecond DA changes may play a role in enhancing reward-cue associations. METH pretreatment reduced tissue DA content in the dorsomedial striatum and nucleus accumbens by ~55%. Analysis of phasic-like DA responses elicited by reinforcing stimulation revealed that METH pretreatment decreased their amplitude and underlying mechanisms for release and uptake to a similar degree as DA content in both striatal subregions. Most importantly, characteristics of DA transients were altered by METH-induced DA terminal loss, with amplitude and frequency decreased and duration increased. These results demonstrate for the first time that denervation of DA neurons alters naturally occurring DA transients and are consistent with diminished phasic DA signaling as a plausible mechanism linking METH-induced striatal DA depletions and cognitive deficits.
© 2013 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  psychostimulant; rat; striatum; transient; voltammetry

Mesh:

Substances:

Year:  2013        PMID: 23574406      PMCID: PMC3699967          DOI: 10.1111/ejn.12209

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  81 in total

1.  Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates.

Authors:  S E McCallum; N Parameswaran; X A Perez; S Bao; J M McIntosh; S R Grady; M Quik
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

2.  Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Authors:  Xiomara A Perez; Neeraja Parameswaran; Luping Z Huang; Kathryn T O'Leary; Maryka Quik
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

3.  Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M Sedler; S J Gatley; E Miller; R Hitzemann; Y S Ding; J Logan
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

Review 4.  Methamphetamine influences on brain and behavior: unsafe at any speed?

Authors:  John F Marshall; Steven J O'Dell
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

5.  Methamphetamine self-administration and the effect of contingency on monoamine and metabolite tissue levels in the rat.

Authors:  Katharine A Brennan; Joyce Colussi-Mas; Caleb Carati; Rod A Lea; Paul S Fitzmaurice; Susan Schenk
Journal:  Brain Res       Date:  2009-12-03       Impact factor: 3.252

6.  Human substantia nigra neurons encode unexpected financial rewards.

Authors:  Kareem A Zaghloul; Justin A Blanco; Christoph T Weidemann; Kathryn McGill; Jurg L Jaggi; Gordon H Baltuch; Michael J Kahana
Journal:  Science       Date:  2009-03-13       Impact factor: 47.728

7.  Methamphetamine causes microglial activation in the brains of human abusers.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Genichi Sugihara; Nori Takei; Etsuji Yoshikawa; Kazuhiko Nakamura; Yasuhide Iwata; Kenji J Tsuchiya; Shiro Suda; Katsuaki Suzuki; Masayoshi Kawai; Kiyokazu Takebayashi; Shigeyuki Yamamoto; Hideo Matsuzaki; Takatoshi Ueki; Norio Mori; Mark S Gold; Jean L Cadet
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

Review 8.  Dopamine-mediated regulation of corticostriatal synaptic plasticity.

Authors:  Paolo Calabresi; Barbara Picconi; Alessandro Tozzi; Massimiliano Di Filippo
Journal:  Trends Neurosci       Date:  2007-03-23       Impact factor: 13.837

9.  Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study.

Authors:  Tom Schonberg; John P O'Doherty; Daphna Joel; Rivka Inzelberg; Yoram Segev; Nathaniel D Daw
Journal:  Neuroimage       Date:  2009-08-12       Impact factor: 6.556

Review 10.  Behavioral dopamine signals.

Authors:  Wolfram Schultz
Journal:  Trends Neurosci       Date:  2007-04-02       Impact factor: 13.837

View more
  12 in total

1.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

2.  Methamphetamine-induced neurotoxicity disrupts pharmacologically evoked dopamine transients in the dorsomedial and dorsolateral striatum.

Authors:  John D Robinson; Christopher D Howard; Elissa D Pastuzyn; Diane L Byers; Kristen A Keefe; Paul A Garris
Journal:  Neurotox Res       Date:  2014-02-22       Impact factor: 3.911

3.  Accelerated development of cocaine-associated dopamine transients and cocaine use vulnerability following traumatic stress.

Authors:  Zachary D Brodnik; Emily M Black; Rodrigo A España
Journal:  Neuropsychopharmacology       Date:  2019-09-20       Impact factor: 7.853

4.  Dynamic Nigrostriatal Dopamine Biases Action Selection.

Authors:  Christopher D Howard; Hao Li; Claire E Geddes; Xin Jin
Journal:  Neuron       Date:  2017-03-09       Impact factor: 17.173

5.  Changes in neural circuitry regulating response-reversal learning and Arc-mediated consolidation of learning in rats with methamphetamine-induced partial monoamine loss.

Authors:  Elissa D Pastuzyn; Kristen A Keefe
Journal:  Neuropsychopharmacology       Date:  2013-10-22       Impact factor: 7.853

6.  Mechanisms Regulating the Association of Protein Phosphatase 1 with Spinophilin and Neurabin.

Authors:  Michael C Edler; Asma B Salek; Darryl S Watkins; Harjot Kaur; Cameron W Morris; Bryan K Yamamoto; Anthony J Baucum
Journal:  ACS Chem Neurosci       Date:  2018-06-01       Impact factor: 4.418

Review 7.  Illicit dopamine transients: reconciling actions of abused drugs.

Authors:  Dan P Covey; Mitchell F Roitman; Paul A Garris
Journal:  Trends Neurosci       Date:  2014-03-20       Impact factor: 13.837

8.  Acute phenylalanine/tyrosine depletion of phasic dopamine in the rat brain.

Authors:  Tatiana A Shnitko; Sarah C Taylor; Sierra J Stringfield; Shannon L Zandy; Roberto U Cofresí; James M Doherty; William B Lynch; Charlotte A Boettiger; Rueben A Gonzales; Donita L Robinson
Journal:  Psychopharmacology (Berl)       Date:  2016-03-05       Impact factor: 4.530

9.  Distinct dose-dependent effects of methamphetamine on real-time dopamine transmission in the rat nucleus accumbens and behaviors.

Authors:  Rohan V Bhimani; Megan Vik; Ken T Wakabayashi; Caitlin Szalkowski; Caroline E Bass; Jinwoo Park
Journal:  J Neurochem       Date:  2021-07-28       Impact factor: 5.546

10.  Characterization of Fast-Scan Cyclic Voltammetric Electrodes Using Paraffin as an Effective Sealant with In Vitro and In Vivo Applications.

Authors:  Eric S Ramsson; Daniel Cholger; Albert Dionise; Nicholas Poirier; Avery Andrus; Randi Curtiss
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.